Today: 21 May 2026
HKEX stock week ahead: IPO restart and China policy calendar set the tone for 0388.HK share price
1 March 2026
2 mins read

HKEX stock week ahead: IPO restart and China policy calendar set the tone for 0388.HK share price

Hong Kong, March 1, 2026, 14:21 HKT — Market’s done for the day.

  • HKEX finished Friday’s session at HK$419.00, gaining 0.87%.
  • IPOs have come roaring back after the holidays, injecting fresh momentum into the listings tape.
  • Beijing’s “Two Sessions” meetings are drawing traders’ attention, with Friday’s U.S. jobs report also in focus as they look for direction on risk appetite.

Hong Kong Exchanges and Clearing (0388.HK) starts the week with investors zeroing in on a single question: will the IPO pipeline keep humming after the Lunar New Year break?

This is important: the bourse operator’s revenue depends on trading and clearing fees, as well as listing charges. When activity picks up, the impact shows up in the numbers quickly.

The stock often moves as a proxy for demand in China-related assets, which make up a significant chunk of turnover and fundraising in Hong Kong. Volumes can swing sharply on policy news from Beijing or shifts in global rates sentiment.

HKEX closed at HK$419.00 on Feb. 27, gaining 0.87% for the session. The stock moved between HK$415.00 and HK$421.40, while 5.89 million shares were traded, Investing.com data showed.

Deals drove the action this week. On Friday, four companies filed for Hong Kong listings, targeting up to HK$4.9 billion ($626 million) in total. Shenzhen Zhaowei Machinery & Electronics headed that group, with trading set for March 9-10, filings show. “As more supply comes to market, investors will increasingly become more selective, focusing on quality deals,” said Art Karoonyavanich, DBS managing director and global head of equity capital markets. Reuters

Despite HKEX logging a record profit of HK$17.8 billion for 2025 and a 30% surge in revenue to HK$29.2 billion, CEO Bonnie Chan kept her outlook measured, according to finews.asia. Chan said there remains “cause for optimism in capital markets” heading into 2026, but signaled she expects volatility ahead. The exchange highlighted an IPO pipeline topping 400 active applications. finews.asia

Late this week, brokers circled back to the same activity narrative. HSBC Global Research bumped up its HKEX target to HK$520 (from HK$510) while sticking with Buy, citing a full-year EPS estimate of HK$14.05 and what it described as unexpectedly firm cost discipline. In the same note, HSBC shaved its 2026 average daily turnover call for Hong Kong equities to HK$252 billion — that’s the daily traded value.

Bank of America Securities is sticking with its Buy rating and a HK$520 target. The firm sees next year’s net profit landing around HK$17.8 billion—which it described as broadly in line—and flagged a jump in average daily turnover to HK$250 billion, up 89% from a year earlier. IPO fundraising also leapt 225% to about HK$287 billion. Still, analysts cautioned, a strong showing this year will make for tougher comparisons in 2026.

Macro events are stacked just after the deal lineup. According to China Daily Asia, the annual CPPCC session — that’s the political advisory gathering held in tandem with the legislature — kicks off in Beijing on March 4. Delegates are expected to review a draft of the 15th Five-Year Plan (2026-2030), along with other agenda items.

China’s National People’s Congress is set to open March 5, with lawmakers poised to take up the government work report, budgets, and policy plans, according to NPC Observer. The session, the site noted, is expected to wrap up March 11.

On Friday, traders will be watching for the next key data point: the U.S. Employment Situation report for February, set to hit at 8:30 a.m. ET on March 6, according to the Bureau of Labor Statistics’ release calendar.

Still, that structure can just as easily work against HKEX. Tepid demand for fresh listings, a misstep from Beijing policymakers, or an abrupt change in global rate outlooks might sap risk appetite and pull trading volumes lower — and that’s what drives those trading fees.

Next up: early-week turnover numbers out of Hong Kong, followed by IPO pricing details. First trades for those listings are slated for March 9-10.

Stock Market Today

  • CyberTech Systems Earnings Raise Cash Flow Concerns Amid Market Stability
    May 20, 2026, 8:56 PM EDT. CyberTech Systems and Software Limited (NSE:CYBERTECH) posted earnings that met market expectations but revealed an accrual ratio of 0.53, indicating weaker free cash flow relative to profit. This financial metric, which measures non-cash earnings, signals potential challenges for upcoming profits as free cash flow of ₹76 million lagged behind reported profit of ₹304.3 million for the year ending March 2026. Despite a 28% annual growth in earnings per share (EPS) over three years, the decline in cash conversion may raise investor caution. The company's accrual ratio improved last year, suggesting the current shortfall could be temporary, but shareholders are advised to monitor cash flow trends closely against profitability for a clearer outlook.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Coinbase stock drops nearly 3% as an insider sale notice lands and traders look to a big data week
Previous Story

Coinbase stock drops nearly 3% as an insider sale notice lands and traders look to a big data week

STI flirts with 5,000: Yangzijiang and AEM set the pace on SGX in the week ahead
Next Story

STI flirts with 5,000: Yangzijiang and AEM set the pace on SGX in the week ahead

Go toTop